• Clarithromycin: A Practical CYP3A Inhibitor Workflow

  2026-08-12

  Build reproducible CYP3A inhibition assays with Clarithromycin, from solvent handling and enzyme preincubation to pharmacokinetic interpretation. A CYP-independent dabigatran comparator adds mechanistic resolution for drug-drug interaction research, statin metabolism interaction studies, and cardiovascular disease drug interaction models.

• (S)-Mephenytoin: CYP2C19 Research Guide

  2026-08-12

  (S)-Mephenytoin is a stereochemically defined CYP2C19 substrate for studying oxidative drug metabolism and anticonvulsive drug metabolism. Its reported in vitro kinetics provide a benchmark for enzyme assays, while hiPSC-derived intestinal organoids provide a human-relevant pharmacokinetic studies platform that still requires direct compound-specific validation.

• Platelet Extravasation in Tumors: CXCR4 Control

  2026-08-11

  The reference study defines platelet transendothelial migration into tumors as a regulated process controlled by stromal CXCL12/CXCR4 signaling, platelet FAK, and PECAM-1. It further shows that platelet trafficking and tumor-promoting secretion are separable functions, providing a framework for studying how vascular exit, granule release, and tumor growth are coordinated.

• AAPH: Designing Reproducible Oxidative Stress Assays

  2026-08-11

  AAPH is a controllable reactive oxygen species generator for modeling lipid peroxidation, erythrocyte hemolysis, and cellular oxidative injury. This guide moves beyond reagent description to explain how radical flux, assay matrix, and endpoint selection determine experimental meaning.

• Berberrubine, Urate Transporters, and JAK2/STAT3

  2026-08-10

  The reference study shows that berberrubine, a major berberine metabolite, reduces potassium oxonate- and hypoxanthine-induced hyperuricemia in mice by coordinating urate transporter regulation, hepatic xanthine oxidase suppression, and inhibition of JAK2/STAT3 signaling. Its integrated design connects serum urate lowering with renal protection and inflammatory control, while also defining important boundaries for translating the findings beyond this acute mouse model.

• Measuring Cancer Drug Responses Beyond Viability

  2026-08-09

  Hannah R. Schwartz’s 2022 dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework that separates proliferative arrest from cell killing and emphasizes their distinct proportions and timing, improving interpretation of in vitro pharmacology.

• Chemistry of Silybin: Structure and Derivatives

  2026-08-08

  Křen and colleagues provide a detailed chemistry-focused review of silybin, the principal flavonolignan associated with milk thistle extract. Its central contributions are the clarification of silybin A and B stereochemistry, the development of separation strategies, and a systematic account of derivatives relevant to solubility, activity, and mechanistic research.

• GI 254023X: ADAM10 Inhibitor Workflows

  2026-08-07

  GI 254023X gives researchers a selective way to connect ADAM10 sheddase activity with Notch1 signaling, Jurkat-cell responses, and endothelial barrier protection. This practical guide combines assay design, dose and solvent controls, cross-domain interpretation, and troubleshooting for more reproducible preclinical studies.

• Dibutyryl-cAMP, Sodium Salt: Data-Driven Solutions for Cell

  2026-08-07

  This scenario-driven guide explores how Dibutyryl-cAMP, sodium salt (SKU B9001) addresses persistent challenges in cell viability, proliferation, and signaling assays. Drawing on quantitative literature and validated best practices, it offers actionable insights for biomedical researchers seeking reliable, reproducible cAMP pathway modulation.

• Forskolin: Adenylate Cyclase Activator for Advanced Cell Ass

  2026-08-06

  Forskolin stands out as a precise adenylate cyclase activator, empowering reproducible cAMP pathway modulation in stem cell and neuroendocrine models. Explore optimized experimental workflows, troubleshooting tactics, and translational insights that set Forskolin apart for both bench and preclinical research.

• Ferroptosis-Gene Signature Predicts HCC Prognosis, Atorvasta

  2026-08-06

  This study establishes a novel prognosis model for hepatocellular carcinoma (HCC) using ferroptosis-related genes and demonstrates that atorvastatin, a known HMG-CoA reductase inhibitor, induces ferroptosis and suppresses HCC cell proliferation and migration. The findings support both biomarker-driven risk stratification and targeted therapy development in liver cancer research.

• Catalpol’s Neuroprotective Mechanisms in Alzheimer’s Disease

  2026-08-05

  The referenced study comprehensively reviews catalpol’s multi-target neuroprotective effects, highlighting its antioxidant, anti-inflammatory, and antiapoptotic actions in Alzheimer’s disease models. These findings support the growing interest in natural product-based interventions for neurodegenerative disorders, with implications for translational research targeting inflammation and metabolic dysfunction.

• CNQX (SKU B6222): Reliable Inhibitor for Glutamatergic Assay

  2026-08-05

  This article provides practical, scenario-driven guidance for leveraging CNQX (SKU B6222) as a selective glutamatergic neurotransmission inhibitor. By addressing real laboratory challenges—from experimental design to vendor selection—it demonstrates how CNQX enhances assay reproducibility and sensitivity, grounded in recent evidence and validated protocols.

• BH3 Mimetics Clear Senescent Cells in TP53 Wild-Type Breast

  2026-08-04

  Ungerleider et al. reveal that BH3 mimetics targeting BCL-XL and MCL1 selectively eliminate chemotherapy-induced senescent breast cancer cells, improving tumor regression and survival in TP53 wild-type models. This mechanistic insight underscores the therapeutic promise of BCL-XL inhibition to overcome persistent residual disease after chemotherapy.

• Omeprazole (A2845) for Reliable H+,K+-ATPase Inhibition Stud

  2026-08-04

  Omeprazole (SKU A2845) is a high-purity H+,K+-ATPase inhibitor, supporting robust research on gastric acid secretion and antiulcer mechanisms. This reagent is not designed for diagnostic or therapeutic use, and should be applied exclusively in controlled laboratory workflows requiring validated potency and selectivity.

15132 records 1/1009 page Next 12345 下5页 Last page